Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

References

• AhrenBWhat mediates the benefits associated with dipeptidyl peptidase-IV inhibition?Diabetologia200548605715770467
   PubMed Web of Science ®Google Scholar
• AhrenBSorhede WinzellMBurkeyBBeta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in miceEur J Pharmacol2005521164816171801
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMLuncefordJSitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM)Diabetes2006a55Suppl 1A462
   Google Scholar
• AschnerPKipnesMLuncefordJSitagliptin monotherapy improved glycemic control in patients with type 2 diabetesDiabetologia2006b49Supl 15
   Google Scholar
• AschnerPKipnesMSLuncefordJKEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care2006c292632717130196
   PubMed Web of Science ®Google Scholar
• BergmanAJStevensCZhouYPharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersClin Ther200628557216490580
   PubMed Web of Science ®Google Scholar
• BrayGMExenatideAm J Health Syst Pharm200663411816484515
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJEfficacy and safety of sitagliptin added to ongoing metformin therapy in type 2 diabetes patients who were inadequately controlled on metformin aloneDiabetologia200649Suppl 15
   Google Scholar
• DeaconCFHolstJJDipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspectiveBiochem Biophys Res Commun20022941412054731
   PubMed Web of Science ®Google Scholar
• DemuthHUMcIntoshCHPedersonRAType 2 diabetes—therapy with dipeptidyl peptidase IV inhibitorsBiochim Biophys Acta20051751334415978877
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab2006315365
   Google Scholar
• FeinglosMNSaadMFPi-SunyerFXEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabet Med20052210162316026367
   PubMed Web of Science ®Google Scholar
• GallwitzBTherapies for the treatment of type 2 diabetes mellitus based on incretin actionMinerva Endocrinol2006311334716682937
   PubMedGoogle Scholar
• HermanGABergmanAYiBTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase–4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin2006a2219394717022853
   PubMed Web of Science ®Google Scholar
• HermanGABergmannJWagnerJASitagliptin, a DPP–4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug–drug interactions (DDI)Diabetologia2006b49Suppl 1481
   Google Scholar
• KarasikACharbonnelBLiuJSitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetesDiabetes200655Suppl 1A 119
   Google Scholar
• KimDWangLBeconiM(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesJ Med Chem2005481415115634008
   PubMed Web of Science ®Google Scholar
• KnudsenLBPridalLGlucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptorEur J Pharmacol1996318429359016935
   PubMed Web of Science ®Google Scholar
• MarguetDBaggioLKobayashiTEnhanced insulin secretion and improved glucose tolerance in mice lacking CD26Proc Natl Acad Sci USA2000976874910823914
   PubMed Web of Science ®Google Scholar
• MentleinRDipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptidesRegul Pept19998592410588446
   PubMed Web of Science ®Google Scholar
• MentleinRGallwitzBSchmidtWEDipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEur J Biochem1993214829358100523
   PubMedGoogle Scholar
• MillerSSt OngeELSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesAnn Pharmacother20064013364316868220
   PubMed Web of Science ®Google Scholar
• MuJWoodsJZhouYPChronic inhibition of dipeptidyl peptidase–4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetesDiabetes200655169570416731832
   PubMed Web of Science ®Google Scholar
• NauckMAEl-OuaghlidiAThe therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1Diabetologia2005486081115761719
   PubMed Web of Science ®Google Scholar
• PospisilikJAMartinJDotyTDipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic ratsDiabetes2003527415012606516
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLSitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM)Diabetes2006a55Suppl 1A 462
   Google Scholar
• RazIHanefeldMXuLEfficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetesDiabetologia2006b49Suppl 1481
   Google Scholar
• RazIHanefeldMXuLEfficacy and safety of the dipeptidyl peptidase–4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia2006c4925647117001471
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPJAddition of sitagliptin to pioglitazone improved glycemecic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetesDiabetologia2006a49Suppl 126
   Google Scholar
• RosenstockJBrazgRAndryukPJAddition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM)Diabetes2006b55Suppl 1A 132A 133
   Google Scholar
• ScottRHartleyPLuoEUse of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI)Diabetes200655Suppl 1A 462
   Google Scholar
• XuLManCDCobelliCSitagliptin improved beta-cell function in patients with type 2 diabetes: a model-based analysisDiabetologia2006a49Suppl 1396
   Google Scholar
• XuLManCDCobelliCSitagliptin improved beta-cell function in patients with type 2 diabetes (T2DM): a model-based analysisDiabetes2006b55Suppl 1A 466
   PubMedGoogle Scholar